13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NVO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NOVO NORDISK A S (NVO), a Healthcare sector company. NVO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of NVO by reported 13-F value include DODGE & COX, LOOMIS SAYLES & CO L P, FRANKLIN RESOURCES, based on the most recent SEC filings. NVO trades on the NYSE exchange and files with the SEC under CIK 353278. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NOVO NORDISK A S directly from SEC EDGAR.

AI Insight: NVO Financial Trends

Equity base has nearly quadrupled since Q4 2018, driven by sustained profit retention and balance-sheet strengthening.

Equity grew from $51.8B (Q4 2018) to $194.0B (Q4 2025), a 3.7× increase over seven years.

Acceleration evident in recent years: equity rose $36.5B from Q4 2023 to Q4 2024, then $50.6B to Q4 2025.

Income statement and cash flow data absent; cannot assess margin quality, profitability trends, or cash generation driving equity growth.

AI Insight: NVO Ratio Trends

Insufficient data to assess Novo Nordisk's financial trends — all ratio fields are blank across the entire dataset.

No operating margin, net profit margin, ROE, ROA, ROIC, or leverage data available for analysis.

Data completeness issue prevents evaluation of operational efficiency, profitability, and capital structure trends.

Get alerted when NVO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NOVO NORDISK A S including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of NVO

Put NVO on your watchlist

Track score changes the day NOVO NORDISK A S files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is NVO a good stock to buy?

13F Pro's AI-powered analysis of NOVO NORDISK A S (NVO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NVO are available on the NVO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NVO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NVO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NOVO NORDISK A S's investment landscape.